Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome

Clinical Cancer Research

Volumn 20, Issue 23, 2014, Pages 6127-6140

  Karlsson, Anna ^a   Jönsson, Mats ^a   Lauss, Martin ^a   Brunnström, Hans ^a   Jonssön, Per ^b   Borg, Åke ^a,b   Jonssön, Göran ^a,b   Ringnér, Markus ^a,b   Planck, Maria ^a   Staaf, Johan ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BRG1 PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PROTEIN KINASE LKB1; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; BOOTSTRAPPING; CANCER GENETICS; CANCER PATIENT; CLINICAL FEATURE; CLUSTER ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; EXOME; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOME ANALYSIS; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; HUMAN GENOME; HUMAN TISSUE; KEAP1 GENE; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG PARENCHYMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; OUTCOME ASSESSMENT; PHENOTYPE; PROMOTER REGION; SMALL CELL LUNG CANCER; SMARCA4 GENE; SMOKING; STK11 GENE; TUMOR SUPPRESSOR GENE; VALIDATION STUDY; ADENOCARCINOMA; CANCER STAGING; CARCINOMA; CASE CONTROL STUDY; COPY NUMBER VARIATION; CPG ISLAND; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; REPRODUCIBILITY; RISK FACTOR; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, NEUROENDOCRINE; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; CPG ISLANDS; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 84918512244     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1087     Document Type: Article

References (50)

1. Jemal A, Bray F, Center M.M., Ferlay J., Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Jones PA, Baylin SB The epigenomics of cancer. Cell 2007; 128: 683-92.
3. The Cancer Genome Atlas Network A. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511:543-50.
4. Shinjo K, Okamoto Y, An B., Yokoyama T, Takeuchi I, Fujii M., et al. Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis 2012; 33: 1277-85.
5. Sandoval J, Mendez-Gonzalez J, Nadal E., Chen G, Carmona FJ, Sayols S, et al A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol 2013; 31:4140-7.
6. Selamat SA, Chung BS, Girard L, Zhang W., Zhang Y, Campan M, et al Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Re 2012; 22: 1197-211.
7. Walter K, Holcomb T, Januario T., Du P, Evangelista M, Kartha N., et al. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin Cancer Res 2012; 18: 2360-73.
8. Hughes LA, Melotte V, de Schrijver J, de Maat M, Smit VT, Bovee J.V., et al. The CpG island methylator phenotype: what's in a name? Cancer Res 2013; 73:5858-68.
9. Wilkerson MD, Yin X, Walter V., Zhao N, Cabanski CR, Hayward M.C., et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS ONE 2012; 7:e36530.
10. Hammerman PS, Lawrence MS, Voet D, Jing R., Cibulskis K, Sivachenko A, et al Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489:519-25.
11. The Cancer Genome Atlas. Available from: http://cancergenome.nih.gov/.
12. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011; 473:43-9.
13. Lauss M, Aine M, Sjodahl G., Veerla S, Patschan O, Gudjonsson S., et al. DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. Epigenetics 2012; 7:858-67.
14. Lauss M, Visne I, Kriegner A., Ringner M, Jonsson G, Hoglund M. Monitoring of technical variation in quantitative high-throughput datasets. Cancer Inform 2013; 12:193-201.
15. Gene Expression Omnibus. Available from: http://www.ncbi.nlm.nih.gov/geo/.
16. Staaf J, Isaksson S, Karlsson A., Jonsson M, Johansson L, Jonsson P., et al. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. Int J Cancer 2012; 1:2020-31.
17. Planck M, Edlund K, Botling J., Micke P, Isaksson S, Staaf J. Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status. PLoS ONE 2013; 8: e78614.
18. Russnes HG, Vollan HK, Lingjaerde O.C., Krasnitz A., Lundin P, Naume B, et al Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2010; 2:38ra47.
19. Fredlund E, Staaf J, Rantala J.K., Kallioniemi O., Borg A, Ringner M. The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Res 2012; 14:R113.
20. Staaf J, Jonsson G, Jonsson M., Karlsson A, Isaksson S, Salomonsson A., et al. Relation between smoking history and gene expression profiles in lung adenocarcinomas. BMC Med Genomics 2012; 5:22.
21. Wilkerson MD, Yin X, Hoadley K.A., Liu Y., Hayward MC, Cabanski CR, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 2010; 16:4864-75.
22. da Huang W., Sherman BT, Lempicki RA Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44-57.
23. Berman BP, Weisenberger DJ, Aman J.F., Hinoue T., Ramjan Z, Liu Y, et al Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet 2012; 44:40-6.
24. Helman E, Naxerova K, Kohane IS DNA hypermethylation in lung cancer is targeted at differentiation-associated genes. Oncogene 2012; 31:1181-8.
25. Easwaran H, Johnstone SE, VanNeste L, Ohm J., Mosbruger T, Wang Q, et al A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res 2012; 22:837-49.
26. Carter SL, Eklund AC, Kohane I.S., Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006; 38:1043-8.
27. Takeuchi T, Tomida S, Yatabe Y., Kosaka T, Osada H, Yanagisawa K., et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006; 24: 1679-88.
28. Yoshihara K, Shahmoradgoli M, Martinez E., Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013; 4:2612.
29. Alexandrov LB, Nik-Zainal S, Wedge D.C., Aparicio SA, Behjati S, Biankin AV, et al Signatures of mutational processes in human cancer. Nature 2013; 500:415-21.
30. Lawrence MS, Stojanov P, Polak P., Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214-8.
31. Karlsson A, Ringner M, Lauss M., Botling J, Micke P, Planck M., et al. Genomic and transcriptional alterations in lung adenocarci-noma in relation to smoking history. Clin Cancer Res 2014; 20: 4912-24.
32. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21:5400-13.
33. CLCGP. A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5:209ra153.
34. Crino L, Weder W, van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v103-15.
35. Chitale D, Gong Y, Taylor B.S., Broderick S., Brennan C, Somwar R, et al An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 2009; 28:2773-83.
36. Hinoue T, Weisenberger DJ, Lange C.P., Shen H., Byun HM, Van Den Berg D, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012; 22:271-82.
37. Chen C, Yin N, Yin B., Lu Q. DNA methylation in thoracic neoplasms. Cancer Lett 2011; 301:7-16.
38. Langevin SM, Kratzke RA, Kelsey KT Epigenetics of lung cancer. Transl Res 2014. S1931-5244(14)00085-1 [pii] 10.1016/j.trsl.2014.03.001 PUBMED: 24686037.
39. Fernandez AF, Assenov Y, Martin-Subero JI, Balint B., Siebert R, Taniguchi H, et al A DNA methylation fingerprint of 1628 human samples. Genome Res 2012; 22:407-19.
40. Jonsson G, Busch C, Knappskog S., Geisler J, Miletic H, Ringner M., et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 2010; 16:3356-67.
41. Pages F, Berger A, Camus M., Sanchez-Cabo F, Costes A, Molidor R., et al. Effector memory T cells, early metastasis, and survival in colo-rectal cancer. N Engl J Med 2005; 353:2654-66.
42. Zhang L, Conejo-Garcia JR, Katsaros D., Gimotty PA, Massobrio M, Regnani G, et al Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13.
43. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010; 29:23-36.
44. Imielinski M, Berger AH, Hammerman P.S., Hernandez B., Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150:1107-20.
45. Prat A, Parker JS, Karginova O, Fan C., Livasy C, Herschkowitz JI, et al Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
46. Tan Q, Wang G, Huang J., Ding Z, Luo Q, Mok T., et al. Epigenomic analysis of lung adenocarcinoma reveals novel DNA methylation patterns associated with smoking. Onco Targets Ther 2013; 6: 1471-9.
47. Nik-Zainal S., Van Loo P, Wedge DC, Alexandrov L.B., Greenman CD, Lau KW, et al. The life history of 21 breast cancers. Cell 2012; 149:994-1007.
48. Raynal NJ, Si J, Taby R.F., Gharibyan V., Ahmed S, Jelinek J, et al DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res 2012; 72:1170-81.
49. Juergens RA, Wrangle J, Vendetti F.P., Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2013; 1:598-607.
50. Wilkerson MD, Hayes DN Consensus Cluster Plus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010; 26:1572-3.